A Study of RO5458640 in Patients With Advanced Solid Tumors

Summary

This multicenter, open-label, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO5458640 in patients with advanced solid tumors. Cohorts of patients will receive ascending doses of RO5458640 intravenously, either weekly or every 2 weeks or every 3 weeks, until disease progression or unacceptable toxicity occurs.

Timeline

Start

2011-07

Primary completion

2013-03

Completion

2013-03

Drugs

Indications